The mechanisms by which alcohol consumption worsens the evolution of chronic hepatitis C (CHC) are poorly understood. We have investigated the possible interaction between hepatitis C virus (HCV) and ethanol in promoting oxidative stress. Circulating IgG against human serum albumin (HSA) adducted with malondialdehyde (MDA-HSA), 4-hydroxynonenal (HNE-HSA), or arachidonic acid hydroperoxide (AAHP-HSA) and against oxidized cardiolipin (Ox-CL) were evaluated as markers of oxidative stress in 145 CHC patients with different alcohol consumption, 20 HCV-free heavy drinkers (HD) without liver disease, and 50 healthy controls. Anti-MDA IgG was increased in CHC patients irrespective of alcohol intake as well as in the HD group. CHC patients with moderate alcohol intake (<50 g ethanol/d), but not HD, also had significantly higher values of anti-AAHP-HSA, anti-HNE-HSA, and anti-Ox-CL IgG (P < .05) than controls. A further elevation (P < .001) of these antibodies was evident in CHC patients with heavy alcohol intake (>50 g ethanol/d). Anti-AAHP and anti-Ox-CL IgG above the 95th percentile in the controls were observed in 24% to 26% of moderate and 58% to 63% of heavy drinkers but only in 6% to 9% of the abstainers. The risk of developing oxidative stress during CHC was increased 3-fold by moderate and 13-to 24-fold by heavy alcohol consumption. Heavy drinking CHC patients had significantly more piecemeal necrosis and fibrosis than abstainers. Diffuse piecemeal necrosis was 4-fold more frequent among alcohol-consuming patients with lipid peroxidation-related antibodies than among those without these antibodies. In conclusion, even moderate alcohol consumption promotes oxidative stress in CHC patients, suggesting a role for oxidative injury in the worsening of CHC evolution by alcohol. (HEPATOLOGY 2003; 38:42-49.) 
The mechanisms by which alcohol consumption worsens the evolution of chronic hepatitis C (CHC) are poorly understood. We have investigated the possible interaction between hepatitis C virus (HCV) and ethanol in promoting oxidative stress. Circulating IgG against human serum albumin (HSA) adducted with malondialdehyde (MDA-HSA), 4-hydroxynonenal (HNE-HSA), or arachidonic acid hydroperoxide (AAHP-HSA) and against oxidized cardiolipin (Ox-CL) were evaluated as markers of oxidative stress in 145 CHC patients with different alcohol consumption, 20 HCV-free heavy drinkers (HD) without liver disease, and 50 healthy controls. Anti-MDA IgG was increased in CHC patients irrespective of alcohol intake as well as in the HD group. CHC patients with moderate alcohol intake (<50 g ethanol/d), but not HD, also had significantly higher values of anti-AAHP-HSA, anti-HNE-HSA, and anti-Ox-CL IgG (P < .05) than controls. A further elevation (P < .001) of these antibodies was evident in CHC patients with heavy alcohol intake (>50 g ethanol/d). Anti-AAHP and anti-Ox-CL IgG above the 95th percentile in the controls were observed in 24% to 26% of moderate and 58% to 63% of heavy drinkers but only in 6% to 9% of the abstainers. The risk of developing oxidative stress during CHC was increased 3-fold by moderate and 13-to 24-fold by heavy alcohol consumption. Heavy drinking CHC patients had significantly more piecemeal necrosis and fibrosis than abstainers. Diffuse piecemeal necrosis was 4-fold more frequent among alcohol-consuming patients with lipid peroxidation-related antibodies than among those without these antibodies. In conclusion, even moderate alcohol consumption promotes oxidative stress in CHC patients, suggesting a role for oxidative injury in the worsening of CHC evolution by alcohol. ( I t is well established that, in about 20% to 25% of the patients with chronic hepatitis C, the disease will progress to cirrhosis or even to hepatocellular carcinoma within 20 years from infection. 1 Among the factors that contribute to the evolution of hepatitis C, the role of alcohol consumption has received increasing attention (for review, see Vento and Cainelli 2 and Peters and Terrault 3 ). An alcohol intake exceeding 40 g/d for women and 60 g/d for men increases by 2-to 3-fold the risk of developing cirrhosis, independently from the duration of HCV infection. 4 According to Corrao and Aricò, the interaction between ethanol and hepatitis C virus (HCV) in promoting cirrhosis is additive for lifetime daily alcohol intake of 50 g/d but becomes synergistic when alcohol consumption exceeds 125 g/d. 5 Nonetheless, a recent report suggests that even moderate alcohol intake (below 30-40 g/d) can promote the progression of fibrosis in patients with HCV infection. 6 In addition, heavy alcohol consumption has also an additive effect with chronic hepatitis C in increasing the risk of hepatocellular carcinoma. 7 Despite the finding that the capacity of ethanol to worsen the evolution of HCV infection is well documented, the mechanisms involved are still poorly under-stood. It has been proposed that alcohol might favor viral replication 8 ; however, other mechanisms are also likely to be involved. Recent studies have documented an association between HCV infection and the presence of both liver and serum markers of oxidative stress. [9] [10] [11] [12] [13] [14] Furthermore, the expression of HCV core protein in transgenic mice or in hepatoma cells lines alters the liver antioxidant status and promotes lipid peroxidation. 15, 16 Ethanol is also known to stimulate the production of reactive oxygen species and hydroxyethyl free radicals and to lower hepatic antioxidant defense. 17 The implication of oxidative damage in human alcohol liver injury is supported by several reports showing an increase in lipid peroxidation markers in patients with alcoholic liver disease. [18] [19] [20] Furthermore, immunohistochemistry has shown the presence of lipid peroxidation products in the areas of liver fatty infiltration, focal necrosis, and fibrosis. 21 These observations prompted us to investigate whether ethanol intake might potentiate oxidative stress in patients with chronic hepatitis C. One of the problems encountered in performing retrospective investigations with serum samples stored frozen for several years is that autooxidation can affect the direct measurement of lipid peroxidation. In the present study, we took advantage of the immunogenic properties of proteins complexed with lipid peroxidation products 22 to evaluate the presence of antibodies against lipid peroxidation-derived antigens as markers of oxidative stress. Indeed, recent studies have shown that the titers of circulating IgG against epitopes derived from the binding of lipid peroxidation products to human albumin or low-density lipoproteins are significantly increased in patients with alcoholic liver disease. [23] [24] [25] Moreover, alcoholic patients also display a significant increase in antibodies that recognize oxidized cardiolipin (Ox-CL). 26 
Patients and Methods
Patient Recruitment. This study included 145 consecutive patients with chronic hepatitis C (CHC) who were referred from 1995 to 2002 to the Internal Medicine Unit at the Ospedale Maggiore della Carità of Novara. HCV infection was assessed by the presence of anti-HCV antibodies using a second-generation enzyme-linked immunosorbent assay (ELISA) (Ortho Diagnostic System, Milano, Italy) and HCV-RNA detection with Amplicor HCV Kit (Roche Diagnostic System). Viral genotype was determined using the INNO-Lipa HCV kit (Innogenetics, Zwijndrecht, Belgium) following the manufacturer's instructions. All the patients were negative for HBV surface antigen and HIV antibodies and had no other known liver diseases.
The lifetime mean daily alcohol intake was assessed at the time of admission, according to a previously described 27 standardized questionnaire presented as part of a survey on life habits. According to alcohol intake in the 5 years that preceded the hospital admission, the patients were divided in abstainers (group A; n ϭ 66), moderate drinkers (group B; n ϭ 53) with ethanol intake below 50 g ethanol/d (range, 10- Fifty healthy controls (38 men, 12 women; mean age, 47 Ϯ 10 years, range 34 to 68 years) originating from the same geographical area were recruited from hospital and university staff. All the controls were drinking within the WHO guidelines for sensible limits. All subjects gave informed consent to the analysis, and the study was planned according to the guidelines of the local ethical committee. Blood samples (5 mL) were taken after an overnight fast for the preparation of serum. All groups were abstinent from alcohol for at least 24 hours prior to the blood sample being taken.
Liver biopsy was performed in 125 patients at the time of the admission to the study using a modified Menghini procedure. On a portion of each sample, hepatic iron concentration was measured by atomic absorption spectroscopy and hepatic iron index calculated as previously reported. 28 The remaining sample was immediately fixed in formalin and embedded in paraffin. Five-micron-thick sections were stained with haematoxylin/eosin, Masson's trichrome, and periodic acid-Sciff after diastase digestion. Each biopsy specimen was evaluated in a blind fashion by an experienced pathologist for the grading and staging according to Ishak's criteria. 29 Steatosis was scored semiquantitatively as the following: 0 ϭ no steatosis, 1 ϭ focal steatosis, 2 ϭ diffuse steatosis in less than 50% of the parenchyma, and 3 ϭ extensive steatosis in more than 50% of the parenchyma.
Antigen Preparation. Malondialdehyde (MDA) and 4-hydroxynonenal (HNE) adducts with human serum albumin (HSA) (MDA-HSA and HNE-HSA, respectively) were prepared by reacting 1 mg/mL HSA with, respectively, 50 mmol/L MDA and 3 mmol/L HNE for 2 hours at 37°C. For the preparation of MDA-HSA adducts, the reaction was carried out in the presence of 100 mmol/L sodium cyanoborohydrure. The unbound aldehydes were removed by overnight dialysis at 4°C against phosphatebuffered saline (PBS), pH 7.4. HSA complexed with reactive products of fatty acid oxidation were generated by thermal autooxidation of arachidonic acid (AAHP-HSA) according to Palinski et al. 22 Briefly, 10 mg arachidonic acid was transferred in a glass vial open to air and kept at 37°C for 72 hours. The yellow-brown reaction products were dissolved in 50 L methanol and suspended by vortexing in 1 mL PBS containing 10 mol/L EDTA, pH 7.4. Aliquots containing 3 mg of oxidized fatty acid were added to 1 mg HSA and incubated overnight at 20°C. AAHP modified HSA was dialysed overnight at 4°C against PBS, pH 7.4. Cardiolipin (88 g/mL in PBS) oxidation was induced by free radicals originating from the thermal decomposition of 1 mmol/L 2,2Ј-azo-bis-(2-amidinopropane) hydrochloride (Polyscience Inc., Warrington, PA). The kinetic of phospholipid oxidation was monitored spectrophotometrically by measuring conjugated diene absorbance at 234 nm. The reaction was stopped by the addition of the antioxidant diphenylphenylendiamine 0.1 mmol/L when the relative difference of absorbance from the solution at time zero was 0.5 optical density (OD). Ox-CL was extracted in 5 mL of chloroform, dried under nitrogen, and resuspended in ethanol (50 g/mL final concentration).
Measurement of Antibodies Titers. Polystyrene microwell plates for ELISA (Nunc-Immuno Maxi-Sorb; Nunc, S/A, Roskilde, Denmark) were coated for 4 hours at 37°C with 0.05 mg/mL of either modified or native HSA solubilized in 0.1 mol/L bicarbonate buffer, pH 9.6. After incubation, the solutions were removed and replaced by 0.3 mL of coating buffer containing 3% bovine serum albumin in PBS, pH 7.4. The plates were further incubated for 1 hour at 37°C to block nonspecific binding sites. The coated wells were washed 3 times with PBS containing 0.25% Triton X-100. The sera of the patients were diluted 1:50 with the coating buffer and added in duplicate as aliquots of 0.20 mL to the appropriate wells and incubated 1 hour at 37°C. After washing 3 times with PBS 0.25% Triton X-100, peroxidase-linked goat antihuman IgG (dilution 1:6,000) (Dako S.P.A., Milano, Italy) were added and incubated for 60 minutes at 37°C. The antibody binding was revealed by the addition of 0.15 mL of a reaction mixture containing 0.4 mg/mL of 1-phenylendiamine, 0.4 L/mL hydrogen peroxide (30%), 5.1 mg/mL citric acid, and 6.1 mg/mL anhydrous Na 2 HPO 4 at pH 5.0. After 15 minutes, the reaction was stopped by adding 50 L 2 N H 2 SO 4 , and absorbances were measured at 490 nm using a Bio-Rad microplate reader (Bio-Rad Laboratories Inc., Hercules, CA). The results were expressed by subtracting the background reactivity with unmodified HSA. For the determination of the immune reactivity toward Ox-CL, ELISA plates (Nunc-Immuno Poly-Sorb Nunc, S/A, Roskilde, Denmark) were coated by adding 30 L of Ox-CL ethanol solution to each well, and the solvent was evaporated under vacuum. The same amount of ethanol was added to reference wells. After 2 washes with PBS 0.3 mL, nonspecific binding sites were blocked by 1 hour incubation at 37°C with 1% (vol/vol) solution of polyethylenglycol compound in PBS, pH 7.4. The coated wells were then washed 3 times with PBS. Patients and controls sera (1:50 dilution in PBS) were incubated for 1 hour at 37°C, and IgG binding was revealed as described above. The results were expressed by subtracting the background reactivity in the wells treated with ethanol alone.
Materials. Malonildialdehyde-bis-dimethylacetal, 4-hydroxynonenal, cardiolipin arachidonic acid, fatty acid free human serum albumin (fraction V), polyethylenglycol compound, and sodium cyanoborohydride were supplied by Sigma Chemical Co. (St. Louis, MO). All other chemicals were of analytical grade and were supplied by Merck (Darmstad, Germany).
Data Analysis and Statistical Calculations. Statistical analyses were performed by Instat-3 statistical software (GraphPad Software Inc, San Diego, CA) using 1-way ANOVA test or Kruskal-Wallis test. Distribution normality of the groups considered was preliminarily evaluated by Kolmogorov and Smirnov test. Relative risk and association analysis were performed by odds ratio and Fisher exact test. Significance was taken at the 5% level.
Results
In this study, we have investigated 145 consecutive patients with CHC and different alcohol consumption. The patients were divided according to the alcohol intake in the 5 years that preceded the hospital admission: abstainers (group A; n ϭ 66), moderate drinkers (group B; n ϭ 53) with ethanol intake below 50 g/d (mean, 24.5 Ϯ 13.3), and heavy drinkers (group C; n ϭ 26) with ethanol intake above 50 g/d; (mean, 101.7 Ϯ 19.9). Female patients were prevalent (68%) in group A, whereas male patients were prevalent in groups B and C (70% and 88%, respectively). The 3 groups were not different for age, smoking, body mass index, prevalence of HCV genotype 1b, and biochemical markers of liver injury, except for the mean globular volume and gamma glutamyltranspeptidase values (Table 1) . The 3 groups also did not differentiate for hepatic iron concentration, whereas serum iron, ferritin content, and transferrin saturation were significantly (P Ͻ .01) higher in alcohol-consuming patients as compared with abstainers ( Table 1) . As reference, we used 50 age-matched healthy controls with ethanol intake less than 20 g/d and 20 HCV-free heavy drinkers consuming more than 80 g/d (mean, 96.8 Ϯ 20.3) without clinical evidence of liver disease or with steatosis only.
As markers of oxidative stress, we have evaluated the presence of circulating IgG against epitopes derived from protein modification by lipid peroxidation products or recognizing Ox-CL. Figure 1 shows that, irrespective of the alcohol intake, CHC patients have a significant (P Ͻ .01) increase over control levels of IgG against human serum albumin adducted with malondialdehyde (MDA-HSA). However, in the absence of alcohol consumption, the titers of the antibodies recognizing Ox-CL or albumin adducted with 4-hydroxynonenal (HNE-HSA) or arachidonic acid hydroperoxide (AAHP-HSA) were not different from the controls (Fig. 1) . A significant elevation (P Ͻ .05) in anti-MDA IgG, without changes in the titers of the other antibodies, was also evident in a group of heavy drinkers without HCV infection (Fig. 1) . On the other hand, CHC patients with moderate alcohol intake (group B) showed titers of IgG against Ox-CL, HNE-HSA, or AAHP-HSA significantly (P Ͻ .05) higher than controls or abstainers. A further significant elevation (P Ͻ .01) of these antibodies is also evident in CHC patients with heavy alcohol intake (group C) (Fig. 1 ). These differences could not be accounted for by differences in circulating IgG because gammaglobulin levels were comparable in the 3 groups (Table 1) .
Taking as threshold values the titers of the different antibodies above the 95th percentile in the controls, an elevation in anti-MDA IgG was evident in 38% of abstaining and in about 52% to 55% of alcohol-consuming CHC patients (Fig. 2) . Alcohol intake did not significantly increase the risk of developing immune response toward MDA-derived antigens (OR 1.47, 95% CI 0.88- 2.46, P ϭ .2). Conversely, the frequency of subjects with antibodies against AAHP-HSA, HNE-HSA, and Ox-CL above the control threshold increased from 6% to 9% in the abstainers to about 22% to 26% in the patients with moderate alcohol consumption, reaching 58% to 63% in the patients with heavy alcohol intake (Fig. 2) . Interestingly, the risk of developing antibodies against Ox-CL or AAHP-HSA in CHC patients with moderate alcohol intake was about 3-fold higher than in the abstainers (OR for anti-Ox-CL IgG: 3.08, 95% CI 1.08-8.81, P ϭ .04) (OR for anti-AAHP-HSA IgG: 4.33, 95% CI 1.15-16.30, P ϭ .03) and further increased by 13-to 24-fold following heavy alcohol intake (OR for anti-Ox-CL IgG: 13.06, 95% CI 3.78-45.14, P Ͻ .001) (OR for anti-AAHP-HSA IgG: 24.57, 95% CI 5.50-109.7, P Ͻ .0001). Moreover, in these latter patients, the immune response against lipid peroxidation antigens was 4-fold more frequent than in moderate alcohol consumers (OR for anti-Ox-CL IgG: 4.23, 95% CI 1.40-12.78, P ϭ .011) (OR for anti-AAHP-HSA IgG: 5.67, 95% CI 1.85-17.38, P ϭ .004). Alcohol intake also appreciably increased the risk of developing antibodies against HNE-HSA (OR for moderate drinkers: 5.91, 95% CI 1.57-22.21, P ϭ .005; OR for heavy drinkers: 5.17, 95% CI 1.05-25.46, P ϭ .05), but no difference was evident between groups B and C (Fig. 2) .
Previous studies have shown an association between liver iron accumulation and the detection of oxidative stress in CHC patients. 9, 12, 13 In our hands, no correlation was evident between hepatic iron concentration or plasma ferritin values and the titers of lipid peroxidation-related antibodies (not shown). Moreover, the above index of iron overload was not significantly different (P Ն .5) between alcohol-consuming patients with either antiOx-CL or anti-AAPH-HSA antibodies above control range and those within the control range (not shown). Altogether, these data indicate that alcohol intake per se is able to promote oxidative stress during chronic hepatitis C, and such an effect is evident already with moderate alcohol consumption.
To investigate whether ethanol-induced oxidative stress might contribute to the progression of CHC, liver biopsy specimens obtained from 125 of the patients were scored for the grading and the staging of hepatic injury according to Ishak's criteria as well as for the degree of steatosis. Figure 3 shows that alcohol consumption did not influence the extension of steatosis. Similarly, both grading and staging were marginally (P ϭ .06) or not significantly different between moderate alcohol consumers and abstinent patients (Fig. 3) . However, CHC patients with heavy alcohol intake showed grading and staging values significantly higher (P Յ .05) than the abstainers (Fig. 3) . CHC patients with heavy alcohol intake also had more piecemeal necrosis (P Յ .05) than both moderate drinkers or abstinent individuals (Fig. 3) . Moreover, in the subjects with high IgG titers against either Ox-CL or AAHP-HSA, diffuse piecemeal necrosis (score Ͼ1) was 4 times more frequent (OR 4.27, 95% CI 1.27-14.24, P ϭ .027; and OR 4.10, 95% CI 1.20-14.03, P ϭ .027, respectively) than in the individuals with these antibodies in the control range. This suggests that oxidative injury might be one of the mechanisms by which alcohol contributes to hepatic damage during HCV infection.
Discussion
The involvement of oxidative injury in the pathogenesis of hepatitis C is suggested by clinical evidence. In particular, patients with chronic hepatitis C show an increase in the serum content of MDA, 8-isoprostane, and protein carbonyls that are associated with a reduction of the antioxidant defenses. [9] [10] [11] [12] [13] [14] Moreover, immunohistochemistry has documented the presence of MDA and 4-hydroxynonenal protein adduct in liver biopsy specimens from CHC patients. 13, 30 The measurement of the antibodies against the different lipid peroxidation-related antigens confirms these observations, revealing that elevated titers of IgG against MDA adducts are evident in 38% to 55% of the CHC patients, independent of the alcohol consumption. However, the combination of HCV infection and alcohol intake promotes the immune response toward other lipid peroxidation products, including HNE, arachidonic acid hydroperoxide (AAHP), and oxidized cardiolipin. Interestingly, the frequency of patients who develop these latter antibodies increases in relation with alcohol intake, being 3 to 4 times higher in moderate drinkers and up to 10 times higher in heavy drinkers. This effect cannot be ascribed to alcohol consumption per se because HCV-free heavy drinkers have anti-AAHP, anti-HNE, and anti-Ox-CL IgG titers comparable with controls. 25, 26 As previously reported, the different antibodies against lipid peroxidation products recognize structurally unrelated antigens. 25 Thus, the development of anti-HNE, anti-AAHP, and Ox-CL IgG by the concomitant presence of alcohol and HCV infection might reflect a further stimulation of oxidative damage that leads to the liver accumulation of a variety of lipid peroxidation products other than MDA. Little is known about the mechanisms by which ethanol can promote oxidative injury during HCV infection. HCV 1b genotype has been associated with a high prevalence of oxidative damage. 12, 31 Among the patients investigated, 1b viral genotype is uniformly distributed in the 3 groups. Other studies have shown a close correlation between liver iron deposition and oxidative injury in CHC patients, suggesting a role for iron-catalyzed reactions. 9, 12, 13 Our data confirm previous observations concerning the association between alcohol intake and an elevation of serum iron marker. 32 However, no relation is appreciable between hepatic iron concentration or plasma ferritin content and the titers of antibodies against lipid peroxidation antigens. Recent reports have demonstrated that the expression of HCV core protein in transgenic mice or in hepatoma cells lines alters the liver antioxidant status and promotes lipid peroxidation, probably by inducing the production of reactive oxygen species (ROS) within the mitochondria. 15, 16 An increase in mitochondrial ROS production has been proposed as one of the causes of ethanol-induced oxidative stress. 33 In addition, cytochrome P4502E1 induction by alcohol promotes the formation of ROS and hydroxyethyl free radicals. 17 Therefore, it is possible that HCV and alcohol might act synergically in stimulating free radical generation as well as in affecting liver antioxidant defenses. This might occur even in the presence of a moderate alcohol intake that is per se insufficient to cause oxidative damage. Consistently, the oral administration of 5% alcohol for 3 weeks doubles the liver content of lipid hydroperoxides in transgenic mice expressing the HCV core protein but is without effect in the wild-type mice. 15 Several studies have investigated the possible role of oxidative injury in the progression of hepatitis C. In particular, oxidative damage is evident in either HCVinfected subjects or in HCV-transgenic mice in the ab- sence of necroinflammatory changes or aminotransferase release. 15, 34 Moreover, the plasma levels of lipid peroxidation products strictly correlate with the release of aminotransferase, 10, 12 whereas oxidative injury ameliorates in the patients that respond to interferon therapy. 11, 13 On this basis, it is tempting to postulate that the stimulation of oxidative stress by alcohol might have a role in worsening the evolution of CHC. In support of this hypothesis, we have observed that heavy drinkers having a high prevalence of lipid peroxidation-related antibodies suffer more severe liver damage than abstainers. Moreover, among CHC patients with alcohol intake, diffuse piecemeal necrosis is 4-fold more frequent in the individuals with antibodies against lipid peroxidation-derived antigens above the control range. This latter observation is particularly important because Serfaty et al. 35 have recently shown that the severity of piecemeal necrosis is an independent risk factor in the progression of fibrosis during CHC.
In conclusion, the data presented are the first evidence that even moderate alcohol consumption worsens oxidative stress in patients with chronic hepatitis C and suggest that oxidative injury might be one of the mechanisms by which alcohol contributes to the progression of chronic hepatitis C.
